JP2010514716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514716A5 JP2010514716A5 JP2009543372A JP2009543372A JP2010514716A5 JP 2010514716 A5 JP2010514716 A5 JP 2010514716A5 JP 2009543372 A JP2009543372 A JP 2009543372A JP 2009543372 A JP2009543372 A JP 2009543372A JP 2010514716 A5 JP2010514716 A5 JP 2010514716A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- aryl
- halogen
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 146
- 150000001875 compounds Chemical class 0.000 claims description 60
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 150000002367 halogens Chemical class 0.000 claims description 47
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 32
- 125000002947 alkylene group Chemical group 0.000 claims description 29
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 19
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 17
- -1 chloro, bromo, methyl Chemical group 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical group NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- UBOWFTITFZWGJE-UHFFFAOYSA-N 1-[4-[(7-chloro-1-oxo-2h-isoquinolin-6-yl)oxy]cyclohexyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C1CCC(OC=2C(=CC=3C(=O)NC=CC=3C=2)Cl)CC1 UBOWFTITFZWGJE-UHFFFAOYSA-N 0.000 claims 1
- AEUJTBWIMOAWAD-UHFFFAOYSA-N 5-(7-chloro-1-phenylmethoxyisoquinolin-6-yl)oxy-1-propylcyclooctan-1-amine Chemical compound C1CCC(CCC)(N)CCCC1OC1=CC2=CC=NC(OCC=3C=CC=CC=3)=C2C=C1Cl AEUJTBWIMOAWAD-UHFFFAOYSA-N 0.000 claims 1
- BLAQPFJXIQQVLI-UHFFFAOYSA-N 6-(1-amino-5-benzyl-5-propylcyclooctyl)oxy-7-chloro-2h-isoquinolin-1-one Chemical compound C1CCC(N)(OC=2C(=CC=3C(=O)NC=CC=3C=2)Cl)CCCC1(CCC)CC1=CC=CC=C1 BLAQPFJXIQQVLI-UHFFFAOYSA-N 0.000 claims 1
- FTXVEMQCWAPCBK-UHFFFAOYSA-N 6-(3-aminocyclobutyl)oxy-7-chloro-2h-isoquinolin-1-one Chemical compound C1C(N)CC1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 FTXVEMQCWAPCBK-UHFFFAOYSA-N 0.000 claims 1
- QAVDNIORQCTAPQ-UHFFFAOYSA-N 6-(5-amino-5-propylcyclooctyl)oxy-7-chloro-2h-isoquinolin-1-one Chemical compound C1CCC(CCC)(N)CCCC1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 QAVDNIORQCTAPQ-UHFFFAOYSA-N 0.000 claims 1
- MMOFTHWIRXCQME-UHFFFAOYSA-N 6-(5-aminocyclooctyl)oxy-7-chloro-2h-isoquinolin-1-one Chemical compound C1CCC(N)CCCC1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 MMOFTHWIRXCQME-UHFFFAOYSA-N 0.000 claims 1
- SUSVCWSIXVRRAR-PWSUYJOCSA-N 6-[(1s,3r)-3-aminocyclopentyl]oxy-2h-isoquinolin-1-one Chemical compound C1[C@H](N)CC[C@@H]1OC1=CC=C2C(=O)NC=CC2=C1 SUSVCWSIXVRRAR-PWSUYJOCSA-N 0.000 claims 1
- ATPNKVBEDMBNII-ZJUUUORDSA-N 6-[(1s,3r)-3-aminocyclopentyl]oxy-7-chloro-2h-isoquinolin-1-one Chemical compound C1[C@H](N)CC[C@@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 ATPNKVBEDMBNII-ZJUUUORDSA-N 0.000 claims 1
- SUSVCWSIXVRRAR-JQWIXIFHSA-N 6-[(1s,3s)-3-aminocyclopentyl]oxy-2h-isoquinolin-1-one Chemical compound C1[C@@H](N)CC[C@@H]1OC1=CC=C2C(=O)NC=CC2=C1 SUSVCWSIXVRRAR-JQWIXIFHSA-N 0.000 claims 1
- ATPNKVBEDMBNII-UWVGGRQHSA-N 6-[(1s,3s)-3-aminocyclopentyl]oxy-7-chloro-2h-isoquinolin-1-one Chemical compound C1[C@@H](N)CC[C@@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 ATPNKVBEDMBNII-UWVGGRQHSA-N 0.000 claims 1
- VHUZNTCMWXTFOL-OLZOCXBDSA-N 6-[(1s,4r)-4-aminocycloheptyl]oxy-2h-isoquinolin-1-one Chemical compound C1C[C@H](N)CCC[C@@H]1OC1=CC=C2C(=O)NC=CC2=C1 VHUZNTCMWXTFOL-OLZOCXBDSA-N 0.000 claims 1
- LVOBNNDCMWWDFJ-NEPJUHHUSA-N 6-[(1s,4r)-4-aminocycloheptyl]oxy-7-chloro-2h-isoquinolin-1-one Chemical compound C1C[C@H](N)CCC[C@@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 LVOBNNDCMWWDFJ-NEPJUHHUSA-N 0.000 claims 1
- PVFBFRSXKVQJQW-UHFFFAOYSA-N 7-chloro-6-(4-morpholin-4-ylcyclohexyl)oxy-2h-isoquinolin-1-one Chemical compound ClC1=CC(C(NC=C2)=O)=C2C=C1OC(CC1)CCC1N1CCOCC1 PVFBFRSXKVQJQW-UHFFFAOYSA-N 0.000 claims 1
- RKWPNYCHGYMKNJ-UHFFFAOYSA-N 7-chloro-6-(4-piperidin-1-ylcyclohexyl)oxy-2h-isoquinolin-1-one Chemical compound ClC1=CC(C(NC=C2)=O)=C2C=C1OC(CC1)CCC1N1CCCCC1 RKWPNYCHGYMKNJ-UHFFFAOYSA-N 0.000 claims 1
- CQGLYILQWAAFLY-UHFFFAOYSA-N 7-chloro-6-(4-pyrrolidin-1-ylcyclohexyl)oxy-2h-isoquinolin-1-one Chemical compound ClC1=CC(C(NC=C2)=O)=C2C=C1OC(CC1)CCC1N1CCCC1 CQGLYILQWAAFLY-UHFFFAOYSA-N 0.000 claims 1
- MEXKGRCWJZUYOU-UHFFFAOYSA-N 7-chloro-6-[4-(4-methylpiperazin-1-yl)cyclohexyl]oxy-2h-isoquinolin-1-one Chemical compound C1CN(C)CCN1C1CCC(OC=2C(=CC=3C(=O)NC=CC=3C=2)Cl)CC1 MEXKGRCWJZUYOU-UHFFFAOYSA-N 0.000 claims 1
- IMADPLMSYDRVLS-UHFFFAOYSA-N 7-chloro-6-[5-(ethylamino)-5-propylcyclooctyl]oxy-2h-isoquinolin-1-one Chemical compound C1CCC(CCC)(NCC)CCCC1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 IMADPLMSYDRVLS-UHFFFAOYSA-N 0.000 claims 1
- KFHRZCOTTJSUOB-UHFFFAOYSA-N 7-methyl-6-(4-pyrrolidin-1-ylcyclohexyl)oxy-2h-isoquinolin-1-one Chemical compound CC1=CC(C(NC=C2)=O)=C2C=C1OC(CC1)CCC1N1CCCC1 KFHRZCOTTJSUOB-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- SDWOXHRFWILPDR-TXEJJXNPSA-N C1C[C@@H](NCC(=O)O)CC[C@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 Chemical compound C1C[C@@H](NCC(=O)O)CC[C@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 SDWOXHRFWILPDR-TXEJJXNPSA-N 0.000 claims 1
- BLEMTIKPXFDAJU-OKILXGFUSA-N C1C[C@@H](NCC(=O)OCC)CC[C@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 Chemical compound C1C[C@@H](NCC(=O)OCC)CC[C@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 BLEMTIKPXFDAJU-OKILXGFUSA-N 0.000 claims 1
- RBLPQZIYIQDVNF-TXEJJXNPSA-N C1[C@@H](NC(C)C)C[C@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 Chemical compound C1[C@@H](NC(C)C)C[C@H]1OC(C(=C1)Cl)=CC2=C1C(=O)NC=C2 RBLPQZIYIQDVNF-TXEJJXNPSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- PRZFNYAWUCGFQC-WGSAOQKQSA-N N([C@H]1CC[C@@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1C)C(=O)CC1CCNCC1 Chemical compound N([C@H]1CC[C@@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1C)C(=O)CC1CCNCC1 PRZFNYAWUCGFQC-WGSAOQKQSA-N 0.000 claims 1
- XVVSITVWSWWQNZ-MXVIHJGJSA-N N([C@H]1CC[C@@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1C)C(=O)CCC1CCNCC1 Chemical compound N([C@H]1CC[C@@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1C)C(=O)CCC1CCNCC1 XVVSITVWSWWQNZ-MXVIHJGJSA-N 0.000 claims 1
- CLDKDHBNXPPJSF-CALCHBBNSA-N N([C@H]1CC[C@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1Cl)C(=O)CC1CCNCC1 Chemical compound N([C@H]1CC[C@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1Cl)C(=O)CC1CCNCC1 CLDKDHBNXPPJSF-CALCHBBNSA-N 0.000 claims 1
- ITBDNRRHMGEVFD-HDICACEKSA-N N([C@H]1CC[C@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1Cl)C(=O)CCC1CCNCC1 Chemical compound N([C@H]1CC[C@H](CC1)OC1=CC2=C(C(NC=C2)=O)C=C1Cl)C(=O)CCC1CCNCC1 ITBDNRRHMGEVFD-HDICACEKSA-N 0.000 claims 1
- VMRBNVKXSNXCEZ-CZMCAQCFSA-N N[C@H]1C[C@H](COc2cc3cc[nH]c(=O)c3cc2Cl)C1 Chemical compound N[C@H]1C[C@H](COc2cc3cc[nH]c(=O)c3cc2Cl)C1 VMRBNVKXSNXCEZ-CZMCAQCFSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06026899 | 2006-12-27 | ||
| EP06026899.2 | 2006-12-27 | ||
| PCT/EP2007/011164 WO2008077551A1 (en) | 2006-12-27 | 2007-12-19 | Cycloalkylamine substituted isoquinolone derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514716A JP2010514716A (ja) | 2010-05-06 |
| JP2010514716A5 true JP2010514716A5 (https=) | 2011-02-03 |
| JP5405314B2 JP5405314B2 (ja) | 2014-02-05 |
Family
ID=38565513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543372A Expired - Fee Related JP5405314B2 (ja) | 2006-12-27 | 2007-12-19 | シクロアルキルアミン置換イソキノロン誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8742116B2 (https=) |
| EP (1) | EP2125745B1 (https=) |
| JP (1) | JP5405314B2 (https=) |
| KR (1) | KR101474228B1 (https=) |
| CN (1) | CN101595094B (https=) |
| AR (1) | AR064492A1 (https=) |
| AU (1) | AU2007338407B2 (https=) |
| BR (1) | BRPI0722064A2 (https=) |
| CA (1) | CA2673917C (https=) |
| CL (1) | CL2007003821A1 (https=) |
| CO (1) | CO6210726A2 (https=) |
| CR (1) | CR10813A (https=) |
| DO (1) | DOP2009000164A (https=) |
| EC (1) | ECSP099467A (https=) |
| ES (1) | ES2625266T3 (https=) |
| GT (1) | GT200900179A (https=) |
| IL (1) | IL199540A (https=) |
| MA (1) | MA31075B1 (https=) |
| MX (1) | MX2009005966A (https=) |
| MY (1) | MY155009A (https=) |
| NI (1) | NI200900108A (https=) |
| NO (1) | NO20092422L (https=) |
| NZ (1) | NZ577980A (https=) |
| RU (1) | RU2457203C2 (https=) |
| SV (1) | SV2009003318A (https=) |
| TN (1) | TN2009000269A1 (https=) |
| TW (1) | TWI434689B (https=) |
| UY (1) | UY30843A1 (https=) |
| WO (1) | WO2008077551A1 (https=) |
| ZA (1) | ZA200903551B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2157480B1 (en) | 2003-04-09 | 2015-05-27 | Nikon Corporation | Exposure method and apparatus, and device manufacturing method |
| TWI360158B (en) | 2003-10-28 | 2012-03-11 | Nikon Corp | Projection exposure device,exposure method and dev |
| TWI385414B (zh) | 2003-11-20 | 2013-02-11 | 尼康股份有限公司 | 光學照明裝置、照明方法、曝光裝置、曝光方法以及元件製造方法 |
| TWI609410B (zh) | 2004-02-06 | 2017-12-21 | 尼康股份有限公司 | 光學照明裝置、曝光裝置、曝光方法以及元件製造方法 |
| WO2007008926A1 (en) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| CN102131784B (zh) * | 2008-06-24 | 2014-08-27 | 赛诺菲-安万特 | 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮 |
| HRP20131040T1 (hr) * | 2008-06-24 | 2013-12-06 | Sanofi | Bi- i policikliäśki supstituirani izokinolin i derivati izokinolina kao inhibitori rho-kinaze |
| PT2313374E (pt) * | 2008-06-24 | 2013-11-29 | Sanofi Sa | Isoquinolinas e isoquinolinonas 6-substituídas |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| DK3811943T3 (da) | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| EP3290407B1 (en) | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| US9399194B2 (en) * | 2014-07-16 | 2016-07-26 | Battelle Energy Alliance, Llc | Methods for treating a liquid using draw solutions |
| ES2735087T3 (es) | 2014-12-24 | 2019-12-16 | Gilead Sciences Inc | Compuestos de pirimidina fusionados para el tratamiento de VIH |
| BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| TWI730032B (zh) * | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
| BR112018016475A2 (en) * | 2016-02-12 | 2018-12-26 | Cytokinetics, Incorporated | tetrahydroisoquinoline derivatives |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3481826B1 (en) | 2016-07-08 | 2021-11-03 | Rigel Pharmaceuticals, Inc. | Tyrosine kinase inhibitors |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
| US12060341B2 (en) | 2017-07-12 | 2024-08-13 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as ROCK inhibitors |
| US11447487B2 (en) | 2017-07-12 | 2022-09-20 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as rock inhibitors |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| CA3189027A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| AR125196A1 (es) | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| JPH06501921A (ja) | 1990-07-31 | 1994-03-03 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 選択されたハロカーボンの触媒平衡化 |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| US5843943A (en) * | 1994-12-29 | 1998-12-01 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| NZ513800A (en) | 1996-08-12 | 2001-09-28 | Welfide Corp | Treatment of diseases using Rho kinase inhibitors |
| JP2852649B2 (ja) | 1997-03-19 | 1999-02-03 | チッソ株式会社 | ポリイミド系硬化膜 |
| JP2001514259A (ja) | 1997-08-29 | 2001-09-11 | ゼネカ・リミテッド | アミノメチルオキソオキサゾリジニルベンゼン誘導体 |
| TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
| US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
| IL150650A0 (en) | 2000-01-20 | 2003-02-12 | Eisai Co Ltd | Piperidine derivatives and pharmaceutical compositions containing the same |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| WO2001064238A2 (en) | 2000-02-29 | 2001-09-07 | Curis, Inc. | Methods and compositions for regulating adipocytes |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| WO2002034712A1 (en) | 2000-10-27 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| AU2003281623B8 (en) * | 2002-07-22 | 2009-06-11 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
| EP1550660A1 (en) | 2002-09-12 | 2005-07-06 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| WO2004105757A2 (en) | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| EP1638939A2 (en) | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| JP4794446B2 (ja) | 2003-09-23 | 2011-10-19 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリン系カリウムチャンネル阻害薬 |
| WO2005030791A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
| JPWO2005035516A1 (ja) | 2003-10-10 | 2006-12-21 | 小野薬品工業株式会社 | 新規縮合複素環化合物およびその用途 |
| WO2005054202A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| JP2005232175A (ja) * | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | ５−置換イソキノリン医薬 |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| KR101373535B1 (ko) | 2005-07-26 | 2014-03-12 | 사노피 | Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체 |
| JP5049970B2 (ja) | 2005-07-26 | 2012-10-17 | サノフイ | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
| TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
| US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
| TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| US7893088B2 (en) * | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
| RU2468011C2 (ru) | 2006-12-27 | 2012-11-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолина и изохинолинона |
| WO2008077555A2 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
-
2007
- 2007-12-19 NZ NZ577980A patent/NZ577980A/en not_active IP Right Cessation
- 2007-12-19 RU RU2009128653/04A patent/RU2457203C2/ru not_active IP Right Cessation
- 2007-12-19 MX MX2009005966A patent/MX2009005966A/es active IP Right Grant
- 2007-12-19 JP JP2009543372A patent/JP5405314B2/ja not_active Expired - Fee Related
- 2007-12-19 AU AU2007338407A patent/AU2007338407B2/en not_active Ceased
- 2007-12-19 CA CA2673917A patent/CA2673917C/en not_active Expired - Fee Related
- 2007-12-19 MY MYPI20092589A patent/MY155009A/en unknown
- 2007-12-19 KR KR1020097013520A patent/KR101474228B1/ko not_active Expired - Fee Related
- 2007-12-19 BR BRPI0722064-2A2A patent/BRPI0722064A2/pt not_active IP Right Cessation
- 2007-12-19 CN CN2007800485284A patent/CN101595094B/zh not_active Expired - Fee Related
- 2007-12-19 WO PCT/EP2007/011164 patent/WO2008077551A1/en not_active Ceased
- 2007-12-19 EP EP07856887.0A patent/EP2125745B1/en active Active
- 2007-12-19 ES ES07856887.0T patent/ES2625266T3/es active Active
- 2007-12-21 AR ARP070105857A patent/AR064492A1/es unknown
- 2007-12-25 TW TW096149803A patent/TWI434689B/zh active
- 2007-12-26 CL CL2007003821A patent/CL2007003821A1/es unknown
- 2007-12-26 UY UY30843A patent/UY30843A1/es unknown
-
2009
- 2009-05-20 CR CR10813A patent/CR10813A/es not_active Application Discontinuation
- 2009-05-22 ZA ZA200903551A patent/ZA200903551B/xx unknown
- 2009-06-02 NI NI200900108A patent/NI200900108A/es unknown
- 2009-06-16 CO CO09062108A patent/CO6210726A2/es not_active Application Discontinuation
- 2009-06-18 US US12/487,479 patent/US8742116B2/en not_active Expired - Fee Related
- 2009-06-24 GT GT200900179A patent/GT200900179A/es unknown
- 2009-06-24 MA MA32036A patent/MA31075B1/fr unknown
- 2009-06-24 IL IL199540A patent/IL199540A/en not_active IP Right Cessation
- 2009-06-24 SV SV2009003318A patent/SV2009003318A/es unknown
- 2009-06-25 TN TNP2009000269A patent/TN2009000269A1/fr unknown
- 2009-06-25 NO NO20092422A patent/NO20092422L/no not_active Application Discontinuation
- 2009-06-26 DO DO2009000164A patent/DOP2009000164A/es unknown
- 2009-06-26 EC EC2009009467A patent/ECSP099467A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514716A5 (https=) | ||
| JP2010514719A5 (https=) | ||
| JP2010514718A5 (https=) | ||
| JP2010514717A5 (https=) | ||
| JP2010514721A5 (https=) | ||
| JP2010514720A5 (https=) | ||
| RU2009128653A (ru) | Замещенные циклоалкиламином производные изохинолона | |
| RU2217142C2 (ru) | Химические соединения | |
| CN102093320B (zh) | 一种可溶性环氧化物水解酶抑制剂 | |
| ES2393630T3 (es) | Derivados de N-(AMINO-HETEROARIL)-1H-INDOL-2-CARBOXAMIDAS, su preparación y su aplicación en terapéutica | |
| CN104193725B (zh) | 有机化合物 | |
| RU2009128693A (ru) | Замещенные производные изохинолина и изохинолинона | |
| JP2006502112A5 (https=) | ||
| RU2009128652A (ru) | Замещенные циклоалкиламином производные изохинолина и изохинолинона | |
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| JP2004531473A5 (https=) | ||
| RU2009128688A (ru) | Замещенные циклоалкиламином производные изохинолина и изохинолинона | |
| FI3743406T3 (fi) | Tmem16a-modulaattoreita | |
| JP2011500694A5 (https=) | ||
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JPWO2015199146A1 (ja) | 固形製剤及びその安定化方法 | |
| CN101213187A (zh) | 作为rho-激酶抑制剂的异喹啉衍生物 | |
| RU2009128690A (ru) | Новые замещенные производные изохинолина и изохинолинона | |
| OA12768A (en) | Nicotinamide derivatives useful as PDE4 inhibitors. | |
| RU96112148A (ru) | Антагонисты рецепторов эндотелина |